Detailed Mechanism Funding and Narrative

Years of mechanism: 2010 2011 2012 2013 2014 2015 2016 2017

Details for Mechanism ID: 10517
Country/Region: Ethiopia
Year: 2016
Main Partner: Hawassa University
Main Partner Program: NA
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $383,705 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Health Systems Strengthening (OHSS) $81,872
Sexual Prevention: Other Sexual Prevention (HVOP) $16,904
Treatment: Adult Treatment (HTXS) $250,639
Treatment: Pediatric Treatment (PDTX) $34,290
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 27
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 20
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 30
GEND_GBV Number of people receiving post-GBV care 2017 50
HRH_PRE By Graduates: Doctors 2017 104
HRH_PRE By Graduates: Laboratory professionals 2017 28
HRH_PRE By Graduates: Midwives 2017 38
HRH_PRE By Graduates: Nurses 2017 39
HRH_PRE By Graduates: Other 2017 63
HRH_PRE Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre 2017 272
HRH_PRE Sum of Graduates disaggregates 2017 272
PP_PREV Aggregated Age/sex: 15+ Female 2017 666
PP_PREV Aggregated Age/sex: 15+ Male 2017 334
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 1,000
PP_PREV Total number of people in the target population 2017 1,000
TX_CURR Aggregated Age/Sex: <15 Female 2017 297
TX_CURR Aggregated Age/Sex: <15 Male 2017 287
TX_CURR Aggregated Age/Sex: 15+ Female 2017 2,596
TX_CURR Aggregated Age/Sex: 15+ Male 2017 1,834
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 5,014
TX_CURR Sum of Aggregated Age/Sex <15 2017 584
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 4,430
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 5,014
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 51
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 49
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 320
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 192
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 612
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 612
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 3,250
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 2,600
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 154
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 149
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 1,346
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 951
TX_PVLS Numerator: Indication: Routine 2017 2,080
TX_PVLS Numerator: Indication: Targeted 2017 520
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 192
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 186
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 1,683
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 1,189
TX_PVLS_den Denominator: Indication: Routine 2017 2,600
TX_PVLS_den Denominator: Indication: Targeted 2017 650
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 19
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 23
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 222
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 122
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 386
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 421
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 21
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 25
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 242
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 133
Cross Cutting Budget Categories and Known Amounts Total: $88,372
Human Resources for Health $81,872
Gender: Gender Based Violence (GBV) $6,500
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation